{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T15:28:49Z","timestamp":1786980529694,"version":"build-2736575974"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","issue":"7","license":[{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T00:00:00Z","timestamp":1747699200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005378","name":"Hacettepe \u00dcniversitesi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100005378","name":"Hacettepe University","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005378","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2025,7]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Backgrounds<\/jats:title>\n                    <jats:p>Dry eye disease (DED) is a very common ocular surface disease that affects millions of people around the world. When we look at the pathogenesis of the disease, it is seen that inflammation plays a role. Ankylosing spondylitis (AS) is the prototype of immune-mediated inflammatory rheumatoid diseases in the spectrum of axial spondyloarthropathies. In studies, many proinflammatory cytokines (TNF-\u03b1, IL-23, IFN-\u03b3), especially IL-17, have been shown in the etiopathogenesis of AS. Recently, anti IL-17 receptor inhibitors (secukinumab) have been using. It selectively binds to the IL-17 receptor, preventing its association with the target receptor. From this point of view, it was aimed to evaluate the blood and tear proinflammatory cytokine levels and ocular surface parameters of the patients treated with secukinumab, before and during the treatment.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This cross-sectional study included 12 patients with AS and 12 healthy individuals. The ocular surface and tear film were assessed using the Ocular Surface Disease Index (OSDI) questionnaire, tear film break-up time (TBUT), ocular surface staining, and Schirmer II test. The blood and tear samples were taken simultaneously. Signs and symptoms of DED were evaluated on the treatment day and 4\u00a0weeks, and 12\u00a0weeks after treatment. Tear and blood samples were taken once at the beginning of the study for the control group. Proinflammatory cytokine levels from collected tear and venous blood samples were examined in Pediatric Immunology laboratory. The tear levels of 30 cytokines were examined. Analyses were made with SPSS 25.0 package program.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Compared to controls, AS patients had higher OSDI (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01), similar corneal staining with fluorescein and lissamine green (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.12), and lower TBUT (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u2009\n                      <jats:italic>0.04<\/jats:italic>\n                      ). OSDI were found to be significantly different in the AS group at the measurement times (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.01). IL-1B, IL-10, IL-13, IL-6, IL-12\/IL-23p40, Rantes, Eotaxin, IL-17A, MIP-1A, GM-CSF, MIP-1B, MCP-1, IL-15, IL-5, IFN-G, IFN-A, TNF-A, IL-2, IL-7, IP-10, IL-2R, MIG, IL-4, and IL-8 levels in the AS serum and tears group did not differ at the first and third months (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009&gt;\u20090.05). IL-1RA measurements showed a significant decrease in the first and third months compared to baseline in the AS serum and tears (\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      The findings of this study showed that there was decreased IL-1RA in patients with AS after secukinumab treatment in tears and serum. Interestingly, lachrymal IL-17 levels were similar but not statistical significant changes with two ocular parameters TBUT and Schirmer\u2019s test, suggesting a pathological role of IL-17 in rheumatological diseases. The results suggest that the inhibition of IL-1RA obtained by systemic administration of secukinumab but does not influence the severity of DED.\n                      <jats:table-wrap>\n                        <jats:table>\n                          <jats:tbody>\n                            <jats:tr>\n                              <jats:td align=\"left\" colspan=\"2\">\n                                <jats:bold>Key Points<\/jats:bold>\n                                <jats:italic>\u2022 Many proinflammatory cytokines (TNF-\u03b1, IL-23, IFN-\u03b3), especially IL-17, have been shown in the etiopathogenesis of ankylosing spondylitis.<\/jats:italic>\n                                <jats:italic>\u2022 IL1 affects the local lymfoid nodes and IL 17 affects the lacrimal gland. IL-17 and its receptor are very important structures for the pathogenesis of inflammation.<\/jats:italic>\n                                <jats:italic>\u2022 Secukinumab is a monoclonal antibody that neutralize the IL 1\u03b2 and IL 17 A.<\/jats:italic>\n                                <jats:italic>\u2022 The findings of this study showed that there was decreased IL-1RA in patients with ankylosing spondylitis after secukinumab treatment in tears and serum.<\/jats:italic>\n                              <\/jats:td>\n                            <\/jats:tr>\n                          <\/jats:tbody>\n                        <\/jats:table>\n                      <\/jats:table-wrap>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1007\/s10067-025-07492-y","type":"journal-article","created":{"date-parts":[[2025,5,20]],"date-time":"2025-05-20T16:48:53Z","timestamp":1747759733000},"page":"2775-2782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Systemic secukinumab treatment in patients with ankylosing spondylitis: the relationship between systemic and tear proinflammatory cytokines and ocular surface findings\u2014a pilot study"],"prefix":"10.1007","volume":"44","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5670-2384","authenticated-orcid":false,"given":"Ozlem","family":"Dikmetas","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasemin","family":"Kapucu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Semih","family":"Co\u015fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nargiz","family":"Rustamova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zehra","family":"Ozsoy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibel","family":"Kocabeyoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umut","family":"Kalyoncu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c7a\u011fman","family":"Tan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0130lhan","family":"Tezcan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Murat","family":"Irkec","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,20]]},"reference":[{"issue":"3","key":"7492_CR1","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1111\/1756-185X.14547","volume":"26","author":"MA Khan","year":"2023","unstructured":"Khan MA, Yong SB, Wei JC (2023) Ankylosing spondylitis: history, epidemiology, and HLA-B27. Int J Rheum Dis 26(3):413\u2013414. https:\/\/doi.org\/10.1111\/1756-185X.14547","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"7492_CR2","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1136\/ard-2022-223296","volume":"82","author":"S Ramiro","year":"2023","unstructured":"Ramiro S, Nikiphorou E, Sepriano A, Ortolan A, Webers C, Baraliakos X, Landewe RBM, Van den Bosch FE, Boteva B, Bremander A, Carron P, Ciurea A, van Gaalen FA, Geher P, Gensler L, Hermann J, de Hooge M, Husakova M, Kiltz U, Lopez-Medina C, Machado PM, Marzo-Ortega H, Molto A, Navarro-Compan V, Nissen MJ, Pimentel-Santos FM, Poddubnyy D, Proft F, Rudwaleit M, Telkman M, Zhao SS, Ziade N, van der Heijde D (2023) ASAS-EULAR recommendations for the management of axial spondyloarthritis: 2022 update. Ann Rheum Dis 82(1):19\u201334. https:\/\/doi.org\/10.1136\/ard-2022-223296","journal-title":"Ann Rheum Dis"},{"key":"7492_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.exer.2020.108294","volume":"201","author":"VL Perez","year":"2020","unstructured":"Perez VL, Stern ME, Pflugfelder SC (2020) Inflammatory basis for dry eye disease flares. Exp Eye Res 201:108294. https:\/\/doi.org\/10.1016\/j.exer.2020.108294","journal-title":"Exp Eye Res"},{"issue":"1","key":"7492_CR4","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/02713683.2018.1519834","volume":"44","author":"KB Garbutcheon-Singh","year":"2019","unstructured":"Garbutcheon-Singh KB, Carnt N, Pattamatta U, Samarawickrama C, White A, Calder V (2019) A review of the cytokine IL-17 in ocular surface and corneal disease. Curr Eye Res 44(1):1\u201310. https:\/\/doi.org\/10.1080\/02713683.2018.1519834","journal-title":"Curr Eye Res"},{"key":"7492_CR5","doi-asserted-by":"publisher","unstructured":"Ogawa Y, Shimizu E, Tsubota K (2018) Interferons and dry eye in Sjogren\u2019s syndrome. Int J Mol Sci 19 (11). https:\/\/doi.org\/10.3390\/ijms19113548","DOI":"10.3390\/ijms19113548"},{"issue":"6","key":"7492_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1080\/14740338.2021.1851363","volume":"20","author":"J Loricera","year":"2021","unstructured":"Loricera J, Galindez-Aguirregoikoa E, Blanco R (2021) Safety of secukinumab for the treatment of active ankylosing spondylitis. Expert Opin Drug Saf 20(6):627\u2013634. https:\/\/doi.org\/10.1080\/14740338.2021.1851363","journal-title":"Expert Opin Drug Saf"},{"issue":"7","key":"7492_CR7","doi-asserted-by":"publisher","first-page":"640","DOI":"10.1097\/00003226-200310000-00008","volume":"22","author":"AJ Bron","year":"2003","unstructured":"Bron AJ, Evans VE, Smith JA (2003) Grading of corneal and conjunctival staining in the context of other dry eye tests. Cornea 22(7):640\u2013650. https:\/\/doi.org\/10.1097\/00003226-200310000-00008","journal-title":"Cornea"},{"key":"7492_CR8","unstructured":"Murat \u0130rke\u00e7 TOSG (2007) Reliability and validity of Turkish translation of the Ocular Surface Disease Index (OSDI) in dry eye syndrome. Invest Ophthalmol Vis Sci :408."},{"issue":"9906","key":"7492_CR9","doi-asserted-by":"publisher","first-page":"1705","DOI":"10.1016\/S0140-6736(13)61134-4","volume":"382","author":"D Baeten","year":"2013","unstructured":"Baeten D, Baraliakos X, Braun J, Sieper J, Emery P, van der Heijde D, McInnes I, van Laar JM, Landewe R, Wordsworth P, Wollenhaupt J, Kellner H, Paramarta J, Wei J, Brachat A, Bek S, Laurent D, Li Y, Wang YA, Bertolino AP, Gsteiger S, Wright AM, Hueber W (2013) Anti-interleukin-17A monoclonal antibody secukinumab in treatment of ankylosing spondylitis: a randomised, double-blind, placebo-controlled trial. Lancet 382(9906):1705\u20131713. https:\/\/doi.org\/10.1016\/S0140-6736(13)61134-4","journal-title":"Lancet"},{"key":"7492_CR10","doi-asserted-by":"publisher","unstructured":"Aljohani S, Jazzar A (2023) Tear cytokine levels in sicca syndrome-related dry eye: a meta-analysis. Diagnostics (Basel) 13 (13). https:\/\/doi.org\/10.3390\/diagnostics13132184","DOI":"10.3390\/diagnostics13132184"},{"issue":"6","key":"7492_CR11","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1001\/jamaophthalmol.2013.195","volume":"131","author":"F Amparo","year":"2013","unstructured":"Amparo F, Dastjerdi MH, Okanobo A, Ferrari G, Smaga L, Hamrah P, Jurkunas U, Schaumberg DA, Dana R (2013) Topical interleukin 1 receptor antagonist for treatment of dry eye disease: a randomized clinical trial. JAMA Ophthalmol 131(6):715\u2013723. https:\/\/doi.org\/10.1001\/jamaophthalmol.2013.195","journal-title":"JAMA Ophthalmol"},{"issue":"6","key":"7492_CR12","doi-asserted-by":"publisher","first-page":"e1","DOI":"10.2165\/11599820-000000000-00000","volume":"51","author":"A Chakraborty","year":"2012","unstructured":"Chakraborty A, Tannenbaum S, Rordorf C, Lowe PJ, Floch D, Gram H, Roy S (2012) Pharmacokinetic and pharmacodynamic properties of canakinumab, a human anti-interleukin-1beta monoclonal antibody. Clin Pharmacokinet 51(6):e1-18. https:\/\/doi.org\/10.2165\/11599820-000000000-00000","journal-title":"Clin Pharmacokinet"},{"issue":"7","key":"7492_CR13","doi-asserted-by":"publisher","first-page":"2240","DOI":"10.1002\/art.20299","volume":"50","author":"V Sankar","year":"2004","unstructured":"Sankar V, Brennan MT, Kok MR, Leakan RA, Smith JA, Manny J, Baum BJ, Pillemer SR (2004) Etanercept in Sjogren\u2019s syndrome: a twelve-week randomized, double-blind, placebo-controlled pilot clinical trial. Arthritis Rheum 50(7):2240\u20132245. https:\/\/doi.org\/10.1002\/art.20299","journal-title":"Arthritis Rheum"},{"issue":"2","key":"7492_CR14","doi-asserted-by":"publisher","first-page":"412","DOI":"10.1111\/bjd.12110","volume":"168","author":"KA Papp","year":"2013","unstructured":"Papp KA, Langley RG, Sigurgeirsson B, Abe M, Baker DR, Konno P, Haemmerle S, Thurston HJ, Papavassilis C, Richards HB (2013) Efficacy and safety of secukinumab in the treatment of moderate-to-severe plaque psoriasis: a randomized, double-blind, placebo-controlled phase II dose-ranging study. Br J Dermatol 168(2):412\u2013421. https:\/\/doi.org\/10.1111\/bjd.12110","journal-title":"Br J Dermatol"},{"issue":"5","key":"7492_CR15","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1136\/annrheumdis-2020-218808","volume":"80","author":"X Baraliakos","year":"2021","unstructured":"Baraliakos X, Gossec L, Pournara E, Jeka S, Mera-Varela A, D\u2019Angelo S, Schulz B, Rissler M, Nagar K, Perella C, Coates LC (2021) Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial. Ann Rheum Dis 80(5):582\u2013590. https:\/\/doi.org\/10.1136\/annrheumdis-2020-218808","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"7492_CR16","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1002\/acr.24025","volume":"71","author":"MM Ward","year":"2019","unstructured":"Ward MM, Deodhar A, Gensler LS, Dubreuil M, Yu D, Khan MA, Haroon N, Borenstein D, Wang R, Biehl A, Fang MA, Louie G, Majithia V, Ng B, Bigham R, Pianin M, Shah AA, Sullivan N, Turgunbaev M, Oristaglio J, Turner A, Maksymowych WP, Caplan L (2019) 2019 update of the American College of Rheumatology\/Spondylitis Association of America\/Spondyloarthritis Research and Treatment Network recommendations for the treatment of ankylosing spondylitis and nonradiographic axial spondyloarthritis. Arthritis Care Res (Hoboken) 71(10):1285\u20131299. https:\/\/doi.org\/10.1002\/acr.24025","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"7492_CR17","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1097\/ICO.0000000000000627","volume":"34","author":"CL Grosskreutz","year":"2015","unstructured":"Grosskreutz CL, Hockey HU, Serra D, Dryja TP (2015) Dry eye signs and symptoms persist during systemic neutralization of IL-1beta by canakinumab or IL-17A by secukinumab. Cornea 34(12):1551\u20131556. https:\/\/doi.org\/10.1097\/ICO.0000000000000627","journal-title":"Cornea"},{"issue":"5","key":"7492_CR18","doi-asserted-by":"publisher","first-page":"802","DOI":"10.1016\/j.berh.2016.10.007","volume":"30","author":"PI Murray","year":"2016","unstructured":"Murray PI, Rauz S (2016) The eye and inflammatory rheumatic diseases: the eye and rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis. Best Pract Res Clin Rheumatol 30(5):802\u2013825. https:\/\/doi.org\/10.1016\/j.berh.2016.10.007","journal-title":"Best Pract Res Clin Rheumatol"},{"issue":"1","key":"7492_CR19","doi-asserted-by":"publisher","first-page":"90","DOI":"10.1001\/archophthalmol.2011.364","volume":"130","author":"W Stevenson","year":"2012","unstructured":"Stevenson W, Chauhan SK, Dana R (2012) Dry eye disease: an immune-mediated ocular surface disorder. Arch Ophthalmol 130(1):90\u2013100. https:\/\/doi.org\/10.1001\/archophthalmol.2011.364","journal-title":"Arch Ophthalmol"},{"issue":"3","key":"7492_CR20","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1016\/j.jtos.2013.02.002","volume":"11","author":"M Alves","year":"2013","unstructured":"Alves M, Fonseca EC, Alves MF, Malki LT, Arruda GV, Reinach PS, Rocha EM (2013) Dry eye disease treatment: a systematic review of published trials and a critical appraisal of therapeutic strategies. Ocul Surf 11(3):181\u2013192. https:\/\/doi.org\/10.1016\/j.jtos.2013.02.002","journal-title":"Ocul Surf"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07492-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-025-07492-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-025-07492-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T09:26:41Z","timestamp":1762334801000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-025-07492-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,20]]},"references-count":20,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7]]}},"alternative-id":["7492"],"URL":"https:\/\/doi.org\/10.1007\/s10067-025-07492-y","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,20]]},"assertion":[{"value":"26 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 May 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 May 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 May 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standard"}},{"value":"The study was approved by the Institutional Review Board (KA-180138) and adhered to the tenets of the Declaration of Helsinki. Institutional Review Board approved this study, with waiver of informed consent.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics statement for the use of human and animal subjects"}},{"value":"The authors who signed the Copyright Transfer Form and submitted it to the editorship are deemed to have given this permission.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"None.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}}]}}